Routes of
administration Oral CAS Number 359625-79-9 ChemSpider 7975049 Molar mass 366.4286 g/mol | Legal status Investigational PubChem CID 9799284 Formula C22H23F2N2O2 | |
 | ||
MIN-101 (former developmental code names CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. As of August 2015, the drug is in phase II clinical trials.
References
MIN-101 Wikipedia(Text) CC BY-SA